Thermo Fisher Scientific CD141 Monoclonal Antibody (JAA17), FITC, eBioscience

Applications

Tested Dilution

Publications

Flow Cytometry (Flow)

5 µL (0.125 µg)/Test

View 1 publication 1 publication

Product Specifications

Species Reactivity

Human

Published species

Human

Host/Isotype

Mouse / IgG2a, kappa

Recommended Isotype Control

Mouse IgG2a kappa Isotype Control (eBM2a), FITC, eBioscience™

Class

Monoclonal

Type

Antibody

Clone

JAA17

Conjugate

FITC FITC FITC

View additional formats

• APC
• PE-Cyanine7
• Request custom conjugation

Excitation/Emission Max

498/517 nm View spectra

Form

Liquid

Concentration

5 µL/Test

Purification

Affinity chromatography

Storage buffer

PBS with 0.2% BSA

Contains

0.09% sodium azide

Storage conditions

4° C, store in dark, DO NOT FREEZE!

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2662434

Product Specific Information

This JAA17 monoclonal antibody recognizes human CD141 also known as thrombomodulin, fetomodulin, or BDCA-3. CD141 is a type I membrane receptor that binds and allosterically activates thrombin. The resulting complex cleaves protein C and the Thrombin Activatable Fibrinolysis Inhibitor (TAFI), initiating an important anticoagulant and anti-fibrinolytic pathway. Soluble thrombomodulin is constitutively present in the serum at a very low level and can be upregulated during inflammation. The anti-inflammatory activity of thrombomodulin results from its ability to block the highly pro-inflammatory activity of thrombin. Thrombomodulin prevents chemotaxis and binding of granulocytes to activated endothelium and inhibits activation of eosinophils and mast cells thereby reducing inflammation. Mutations in the CD141 gene result in thromboembolic disease, also known as inherited thrombophilia. Although expressed across many tissues and cell types, its highest expression has been reported on the luminal surface of vascular endothelial cell. In the immune system the highest expression can be observed on myeloid cells, including dendritic cells, macrophages and blood monocytes. In humans, CD141 is commonly used as a marker of cross-presenting dendritic cells in both lymphoid and non-lymphoid tissues. Retinoic acid has been shown to upregulate CD141 expression on human monocyte-derived dendritic cells and primary human dendritic cells.

The JAA17 antibody will recognize CD141 on cells that have been formaldehyde-fixed and permeabilized.

This JAA17 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 µL (0.125 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.

Filtration: 0.2 µm post-manufacturing filtered.

Target Information

Thrombomodulin (TM) is also known as Fetomodulin (FM), endothelial anticoagulant protein, or glycoprotein P112. Thrombomodulin contains six repeated domains homologous with epidermal growth factor (EGF) and an amino terminal domain homologous to lectin-like protein. Through its accelerated activation of protein C, synthesis of TM is one of several mechanisms important in maintaining thrombo-resistance and thus reducing clot formation on the surface of the endothelial cells. Immunohistochemical staining of formalin-fixed tissue for TM has been used for the study of a variety of vascular tumors, meningiomas and choriocarcinomas.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.